HAMBURG, Germany, June 30 -- Evotec Technologies GmbH, a supplier of technologies for life sciences and pharmaceutical drug discovery, has acquired Carl Zeiss Group's UHTS (ultrahigh throughput screening) business unit. As part of the transaction, Evotec received exclusive rights to Zeiss’ UHTS product portfolio, including its plate::vision reader, plate::explorer UHTS system and plate::works software. It also assumed the service responsibility for the installed base of the instruments, including ten UHTS systems that are in operation at pharmaceutical companies.
"Carl Zeiss, as a major supplier of life science instrumentation, has decided to shift its business focus in drug discovery away from UHTS," said Stefan Friedrichowski, vice president and general manager of Carl Zeiss' Advanced Imaging Microscopy Division. "The transfer of our UHTS business to Evotech ensures the best support for our customers, and the synergy of both companies’ technologies and know-how guarantees the continuation of a high standard of customer support and a great potential for further developments."
For more information, visit: www.evotec-technologies.com